Displaying publications 1 - 20 of 469 in total

  1. Matched MeSH terms: Pneumonia
  2. Macaulay TS
    Matched MeSH terms: Pneumonia
  3. Matched MeSH terms: Pneumonia
  4. Matched MeSH terms: Pneumonia
  5. Nur Munirah I, Chidambaram SK
    Med J Malaysia, 2022 01;77(1):92-94.
    PMID: 35087002
    Spontaneous pneumomediastinum is a rare condition in viral pneumonia. However, it can arise spontaneously in COVID-19 patients with no other risk factors. Here we present four cases of spontaneous pneumomediastinum in patients with COVID-19 pneumonia with no other precipitating factors.
    Matched MeSH terms: Pneumonia, Viral*
  6. Alroomi M, Rajan R, Omar AA, Alsaber A, Pan J, Fatemi M, et al.
    Immun Inflamm Dis, 2021 Dec;9(4):1648-1655.
    PMID: 34438471 DOI: 10.1002/iid3.517
    INTRODUCTION: This study aims to investigate in-hоsрitаl mоrtаlity in severe асute resрirаtоry syndrоme соrоnаvirus 2 раtients strаtified by serum ferritin levels.

    METHODS: Patients were stratified based on ferritin levels (ferritin levels ≤ 1000 or >1000).

    RESULTS: Approximately 89% (118) of the patients with ferritin levels > 1000 had pneumonia, and 51% (67) had hypertension. Fever (97, 73.5%) and shortness of breath (80, 61%) were two major symptoms among the patients in this group. Logistic regression analysis indicated that ferritin level (odds ratio [OR] = 0.36, 95% confidence interval [CI] = 0.21-0.62; p pneumonia (OR = 8.48, 95% CI = 3.02-35.45; p  1000.

    CONCLUSION: In this study, higher levels of serum ferritin were found to be an independent predictor of in-hоsрitаl mоrtаlity.

    Matched MeSH terms: Pneumonia*
  7. Kofi Ayittey F, Dzuvor C, Kormla Ayittey M, Bennita Chiwero N, Habib A
    J Med Virol, 2020 Apr;92(4):403-407.
    PMID: 32017153 DOI: 10.1002/jmv.25695
    Matched MeSH terms: Pneumonia*; Pneumonia, Viral
  8. Chiang CY, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, et al.
    Eur Respir J, 2020 10;56(4).
    PMID: 32978310 DOI: 10.1183/13993003.03054-2020
    Matched MeSH terms: Pneumonia, Viral*
  9. Kow CS, Hasan SS, Thiruchelvam K, Aldeyab M
    Br J Anaesth, 2021 03;126(3):e108-e110.
    PMID: 33358046 DOI: 10.1016/j.bja.2020.12.002
    Matched MeSH terms: Pneumonia*
  10. Chase JG, Chiew YS, Lambermont B, Morimont P, Shaw GM, Desaive T
    Crit Care, 2020 07 10;24(1):415.
    PMID: 32650807 DOI: 10.1186/s13054-020-03152-6
    Matched MeSH terms: Pneumonia, Viral*
  11. KADRI ZN
    Med J Malaya, 1959 Jun;13:292-7.
    PMID: 14408341
    Matched MeSH terms: Pneumonia/radiography*
  12. Mehta M, Paudel KR, Shukla SD, Allam VSRR, Kannaujiya VK, Panth N, et al.
    J Control Release, 2021 09 10;337:629-644.
    PMID: 34375688 DOI: 10.1016/j.jconrel.2021.08.010
    Nuclear factor κB (NFκB) is a unique protein complex that plays a major role in lung inflammation and respiratory dysfunction. The NFκB signaling pathway, therefore becomes an avenue for the development of potential pharmacological interventions, especially in situations where chronic inflammation is often constitutively active and plays a key role in the pathogenesis and progression of the disease. NFκB decoy oligodeoxynucleotides (ODNs) are double-stranded and carry NFκB binding sequences. They prevent the formation of NFκB-mediated inflammatory cytokines and thus have been employed in the treatment of a variety of chronic inflammatory diseases. However, the systemic administration of naked decoy ODNs restricts their therapeutic effectiveness because of their poor pharmacokinetic profile, instability, degradation by cellular enzymes and their low cellular uptake. Both structural modification and nanotechnology have shown promising results in enhancing the pharmacokinetic profiles of potent therapeutic substances and have also shown great potential in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. In this review, we examine the contribution of NFκB activation in respiratory diseases and recent advancements in the therapeutic use of decoy ODNs. In addition, we also highlight the limitations and challenges in use of decoy ODNs as therapeutic molecules, cellular uptake of decoy ODNs, and the current need for novel delivery systems to provide efficient delivery of decoy ODNs. Furthermore, this review provides a common platform for discussion on the existence of decoy ODNs, as well as outlining perspectives on the latest generation of delivery systems that encapsulate decoy ODNs and target NFκB in respiratory diseases.
    Matched MeSH terms: Pneumonia*
  13. Mohamed Faisal AH, Petrick P, Andrea YL Ban, Roslina AM
    Pneumococcal pneumonia is the commonest type of bacterial pneumonia worldwide. In Malaysia, the reported incidence of pneumococcal pneumonia is low. This may be due to poor sensitivity of conventional methods. The use of BinaxNOW, a urinary antigen test for Streptococcus pneumoniae can aid in the diagnosis of pneumococcal pneumonia.
    Matched MeSH terms: Pneumonia, Pneumococcal; Pneumonia, Bacterial
  14. Baqer AA, Nor NSM, Alagely HS, Musa M, Adnan NA
    Pol Merkur Lekarski, 2023;51(1):35-41.
    PMID: 36960898 DOI: 10.36740/Merkur202301105
    OBJECTIVE: Aim: Klebsiella pneumonia has emerged as an increasingly important cause of community-acquired nosocomial infections and many of these strains are highly virulent and exhibit a strong propensity to spread. Infections cause by K. pneumonia produces carbapen¬emase (KPC) enzyme and can be difficult to treat since only a few antibiotics are effective against them. Bacteriophage targeting this strain can be an alternative treatment. Characterisation of bacteriophage is utmost important in assisting the application of bacteriophage in phage therapy.

    PATIENTS AND METHODS: Materials and methods: In the present study, the lytic bacteriophage, k3w7, isolated by the host Klebsiella pneumoniae kP2 was characterised using transmission electron microscope (TEM), plaque assay, and restriction digestive enzyme to investigate mor¬phology, host spectrum, bacteriophage life cycle and stability accordingly.

    RESULTS: Results and conclusions: As shown by TEM, k3w7 was observed to have the characteristic of icosahedral heads 100 nm and contractile sheaths 120 nm suggesting it belongs to the family of myoviridae.The Investigation has done on the phage growth cycle showed a short latent period of 20 min and a burst size of approximately 220 plaque forming units per infected cell. Stability test showed the phage was stable over a wide range of pH and temperatures. According to restriction analysis, k3w7 had 50 -kb double-stranded DNA genome as well as the heterogeneous nature of genetic material. These findings suggest that K3W7 has a potential use in therapy against infections caused by K. pneumonia produces carbapenemase.

    Matched MeSH terms: Klebsiella pneumoniae; Pneumonia*
  15. Nathan AM, de Bruyne JA
    Indian J Pediatr, 2015 Jul;82(7):660-1.
    PMID: 25514886 DOI: 10.1007/s12098-014-1640-z
    Matched MeSH terms: Pneumonia*; Pneumonia, Bacterial/drug therapy
  16. Ng BH, Mat WRW, Abeed NNN, Hamid MFA, Yu-Lin AB, Soo CI
    Respirol Case Rep, 2020 Apr;8(3):e00538.
    PMID: 32076554 DOI: 10.1002/rcr2.538
    Liquid silicone (polydimethylsiloxane) is an inert material that is commonly used for cosmetic purpose. Silicone embolization syndrome (SES) can rapidly progress to pneumonitis as a consequence of the injection of nonmedical-grade liquid silicone. We describe a case of severe silicone pneumonitis complicated with acute respiratory distress syndrome and bilateral pneumothorax secondary to silicone gluteal augmentation. In this case report, we aim to discuss our experience and approach in managing an uncommon case of SES.
    Matched MeSH terms: Pneumonia
  17. Hamid FA, Hasbullah AHH, Ban AY
    Breathe (Sheff), 2020 Dec;16(4):200065.
    PMID: 33447285 DOI: 10.1183/20734735.0065-2020
    Can you diagnose this patient with recurrent pneumonia and myasthenia gravis? https://bit.ly/2IBaxC1.
    Matched MeSH terms: Pneumonia
  18. Loh SG
    Med J Malaya, 1951;5.
    A report is given of 60 cases of bronchopneumonia in infants treated with Aureomycin during a period of 4 months, Aureomycin was given orally in a mixture. Dosage depended on the severity of the infection, the age and weight of the patient. The results of this series are compared with a series of penicillin treated cases and showed a distinct improvement. The cure rate of Aureomycin treated cases is about 70%.
    Matched MeSH terms: Pneumonia
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links